First-in-class therapy for autoimmune disease
Artax is discovering small molecules that target Nck, a key cytoplasmic adapter protein, recently discovered to play a key role in T-cell signalling and activation.
The Artax approach has the potential to reduce auto-immunity without affecting the ability of the immune system to respond to an infectious challenge.
CEO Dr. Rob Armstrong
Advent Contact Alan Walts
Advent invested in the Series B in 2015.
Private Companies
Artax Biopharma presents new preclinical data on Nck modulators at 2025 AAD Annual Meeting
Press Release. Artax Biopharma presents new preclinical data on Nck modulators at 2025 AAD Annual Meeting Nck modulator reduced evidence of inflammation in an animal model of dermal…
Read More
Artax Biopharma achieves clinical validation of first-in-class, oral, Nck modulator AX-158 for autoimmune disease in phase 2a study
Press Release. Artax Biopharma achieves clinical validation of first-in-class, oral, Nck modulator AX-158 for autoimmune disease in phase 2a study Novel breakthrough: first molecule to modulate the fundamental mechanism…
Read More
Artax Granted Clinical Trial Authorization for AX-158 Phase 2a Psoriasis Study
Press Release. Patient Enrollment Expected to Begin by Year End Phase 2a Study Seeks to Demonstrate the Safety and Efficacy of AX-158 in Patients with Mild-to-Moderate Psoriasis, Further Advancing…
Read More
Artax Biopharma Announces Positive Phase 1 Results for AX-158, Company’s First-in-Class Oral Immunomodulator Developed to Treat T Cell-Mediated Diseases
Press Release. Artax Biopharma Announces Positive Phase 1 Results for AX-158, Company’s First-in-Class Oral Immunomodulator Developed to Treat T Cell-Mediated Diseases Phase 1 Findings Demonstrated that Investigational Agent…
Read More
Artax Biopharma Expands Company’s Scientific Advisory Board
Press Release. Company Welcomes James G. Krueger, M.D., Ph.D., and Ajay Nirula, M.D., Ph.D., Both Experts in T-Cell-Mediated Diseases. Cambridge, MA, November 15, 2022 - Artax Biopharma, Inc., a…
Read More
Artax Biopharma Closes Financing to Advance Clinical Stage First-in- Class Oral Immunomodulator to Treat T Cell-Mediated Diseases
Press Release. Close of $26 Million Funds Immunomodulation Candidate AX-158 Development Adds New Investors Eli Lilly and Company and Sound Bioventures Cambridge, MA, May 11, 2022 - Artax…
Read More
Artax Biopharma Announces First-in-Human Dosing in Phase 1 Clinical Trial for AX-158, Company’s First-in-Class Oral Immunomodulator to Treat T Cell-Mediated Diseases
Press Release. The Phase 1 Trial, Expected to Conclude in 2022, Will Evaluate Safety, Exposure, and Pharmacokinetics of AX-158 in Healthy Volunteers AX-158, a Novel, Oral Small Molecule Immunomodulating…
Read More
Artax Biopharma Granted MHRA Clinical Trial Authorization for AX-158
Press Release. Authorization Represents Start of Clinical Program for Company’s Global Platform of T Cell-Mediated Diseases Phase 1 Clinical Trial Expected to Start in Second Half of this Year…
Read More
Artax Biopharma Announces the Formation of Scientific Advisory Board to Advance Autoimmune Disease Therapy AX-158
Press Release. Renowned Global Leaders are Experts in Immunology, Autoimmune Disease, and T Cell Signaling Cambridge, Mass., June 24, 2020 - Artax Biopharma, Inc., a biotechnology company focused on…
Read More
Artax Biopharma Announces Series B Financing Extension to Advance First-in-Class Autoimmune Disease Therapy
Press Release. - Extension Brings in Additional Investor - Cambridge, MA, June 4, 2020 - Artax Biopharma, Inc., a biotechnology company focused on transforming autoimmune disease treatment, today announces…
Read More
Artax Biopharma Appoints Joseph Lobacki as Chief Executive Officer, Announces Expanded Management Team
Press Release. Autoimmune Disease Company Hires Life Science Industry Experts to Lead Company Through Next Stage into Human Clinical Studies with Novel Oral Small Molecule AX-158 Cambridge, MA, May…
Read More
